Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Hormone Research in Paediatrics Pub Date : 2025-02-27 DOI:10.1159/000544181

Ian Marpuri, Mitchell E Geffner, Lily C Chao

{"title":"Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty.","authors":"Ian Marpuri, Mitchell E Geffner, Lily C Chao","doi":"10.1159/000544181","DOIUrl":null,"url":null,"abstract":"Introduction: Histrelin acetate implant (HI) is an approved treatment option for children with central precocious puberty. Implant duration has been reported to surpass the recommended replacement interval of 1-2 years. Implant breakage is a known potential adverse effect during the extraction procedure. However, the bioactivity of the retained fragment has not been reported previously.Case presentation: We present 3 cases of females with central precocious puberty, who received HI for pubertal suppression and experienced implant breakage during extraction. In 2 cases, the retained fragment suppressed pubertal hormone for 5 years. In the third case, the HI was left in place due to loss of follow-up, and the patient was amenorrheic for the next 6 years. In all 3 cases, menstruation occurred after the HI fragments were surgically removed.Conclusion: Our case series demonstrates that retained HI fragment can be bioactive for up to 5 years. If HI breakage occurs during removal, ultrasound localization and surgical extraction of the fragment should be performed.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":" ","pages":"1-5"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Research in Paediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544181","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Histrelin acetate implant (HI) is an approved treatment option for children with central precocious puberty. Implant duration has been reported to surpass the recommended replacement interval of 1-2 years. Implant breakage is a known potential adverse effect during the extraction procedure. However, the bioactivity of the retained fragment has not been reported previously.

Case presentation: We present 3 cases of females with central precocious puberty, who received HI for pubertal suppression and experienced implant breakage during extraction. In 2 cases, the retained fragment suppressed pubertal hormone for 5 years. In the third case, the HI was left in place due to loss of follow-up, and the patient was amenorrheic for the next 6 years. In all 3 cases, menstruation occurred after the HI fragments were surgically removed.

Conclusion: Our case series demonstrates that retained HI fragment can be bioactive for up to 5 years. If HI breakage occurs during removal, ultrasound localization and surgical extraction of the fragment should be performed.

查看原文本刊更多论文

导言：醋酸组织生长因子植入剂（HI）是一种已获批准的治疗中枢性性早熟儿童的方法。据报道，植入物的持续时间超过了建议的 1 至 2 年更换间隔。众所周知，种植体破损是拔牙过程中可能出现的不良反应。然而，关于残留片段的生物活性以前还没有报道。病例介绍我们介绍了三例患有中枢性性早熟的女性病例，她们因青春期抑制而接受了 HI 治疗，并在拔除过程中发生了植入物破损。在其中两个病例中，残留的片段抑制了青春期激素达五年之久。在第三个病例中，由于失去了随访，HI 被留在了原位，患者在接下来的六年中一直闭经。在这三个病例中，月经都是在手术切除 HI 碎片后出现的。结论我们的系列病例表明，保留的 HI 片段在长达 5 年的时间里仍具有生物活性。如果在摘除过程中 HI 发生断裂，应进行超声定位并通过手术取出碎片。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hormone Research in Paediatrics ENDOCRINOLOGY & METABOLISM-PEDIATRICS

CiteScore

4.90

自引率

6.20%

发文量

审稿时长

4-8 weeks

期刊介绍： The mission of ''Hormone Research in Paediatrics'' is to improve the care of children with endocrine disorders by promoting basic and clinical knowledge. The journal facilitates the dissemination of information through original papers, mini reviews, clinical guidelines and papers on novel insights from clinical practice. Periodic editorials from outstanding paediatric endocrinologists address the main published novelties by critically reviewing the major strengths and weaknesses of the studies.